retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity A review of an investigational drug retatrutide, a novel agent for the treatment of | European Journal of Clinical Pharmacology The Road towards Triple Agonists:

When compared to matched normal thyroid tissue, both benign (human follicular adenomas, or FTAs) and malignant (follicular (FTC) and papillary thyroid carcinoma (PTC)) lesions were found to have elevated nuclear levels of 8-oxo-dG (118) which most likely reflects the detrimental effects of prolonged exposure to chronic OxS seen during thyroid cancer (118)

Removal from Category 2 does not automatically grant Category 1 status

GIP also plays a role in insulin release and appears to enhance the fat-loss effects of GLP-1 agonism while potentially mitigating some side effects

Tesamorelin is available as a standalone 1-peptide protocol or as part of a multi-peptide stack at Perfect B in Doral, FL